buspirone has been researched along with Stroke in 8 studies
Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.
buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
Excerpt | Relevance | Reference |
---|---|---|
" Buspirone was administered to 16 depressed poststroke (DPS), 10 non-depressed post-stroke (NDPS) patients, and 10 male healthy controls (HCs), to evaluate serotonin (5-HT) function." | 7.70 | The prolactin response to buspirone in poststroke depression: a preliminary report. ( Erol, A; Sevinçok, L, 2000) |
"Treatment with buspirone (3 mg/kg p." | 5.91 | Beneficial effects of buspirone in endothelin-1 induced stroke cachexia in rats. ( Joshi, M; Patel, BM; Shah, D; Shah, J, 2023) |
" The second trial randomised 94 stroke patients, also with co-morbid anxiety and depression, to receive buspirone hydrochloride or standard care." | 4.87 | Interventions for treating anxiety after stroke. ( Campbell Burton, CA; Gillespie, D; Holmes, J; Knapp, P; Lightbody, CE; Murray, J; Watkins, CL, 2011) |
" Buspirone was administered to 16 depressed poststroke (DPS), 10 non-depressed post-stroke (NDPS) patients, and 10 male healthy controls (HCs), to evaluate serotonin (5-HT) function." | 3.70 | The prolactin response to buspirone in poststroke depression: a preliminary report. ( Erol, A; Sevinçok, L, 2000) |
"Treatment with buspirone (3 mg/kg p." | 1.91 | Beneficial effects of buspirone in endothelin-1 induced stroke cachexia in rats. ( Joshi, M; Patel, BM; Shah, D; Shah, J, 2023) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (25.00) | 29.6817 |
2010's | 4 (50.00) | 24.3611 |
2020's | 2 (25.00) | 2.80 |
Authors | Studies |
---|---|
Shah, D | 1 |
Joshi, M | 1 |
Shah, J | 1 |
Patel, BM | 1 |
Conti, S | 1 |
Spalletti, C | 1 |
Pasquini, M | 1 |
Giordano, N | 1 |
Barsotti, N | 1 |
Mainardi, M | 1 |
Lai, S | 1 |
Giorgi, A | 1 |
Pasqualetti, M | 1 |
Micera, S | 1 |
Caleo, M | 1 |
Knapp, P | 2 |
Campbell Burton, CA | 2 |
Holmes, J | 2 |
Murray, J | 2 |
Gillespie, D | 2 |
Lightbody, CE | 2 |
Watkins, CL | 2 |
Chun, HY | 1 |
Lewis, SR | 1 |
van der Worp, HB | 1 |
Macleod, MR | 1 |
Bath, PM | 1 |
Demotes, J | 1 |
Durand-Zaleski, I | 1 |
Gebhardt, B | 1 |
Gluud, C | 1 |
Kollmar, R | 2 |
Krieger, DW | 1 |
Lees, KR | 1 |
Molina, C | 1 |
Montaner, J | 1 |
Roine, RO | 1 |
Petersson, J | 1 |
Staykov, D | 1 |
Szabo, I | 1 |
Wardlaw, JM | 1 |
Schwab, S | 2 |
Schellinger, PD | 1 |
Steigleder, T | 1 |
Köhrmann, M | 1 |
Lyden, P | 1 |
Ernstrom, K | 1 |
Cruz-Flores, S | 1 |
Gomes, J | 1 |
Grotta, J | 1 |
Mullin, A | 1 |
Rapp, K | 1 |
Raman, R | 1 |
Wijman, C | 1 |
Hemmen, T | 1 |
Sevinçok, L | 1 |
Erol, A | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
EuroHYP-1: European Multicentre, Randomised, Phase III Clinical Trial of Therapeutic Hypothermia Plus Best Medical Treatment Versus Best Medical Treatment Alone for Acute Ischaemic Stroke[NCT01833312] | Phase 3 | 98 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to Slow recruitment, cessation of funding) | ||
Phase 2/3 Study of Intravenous Thrombolysis and Hypothermia for Acute Treatment of Ischemic Stroke[NCT01123161] | Phase 2/Phase 3 | 120 participants (Actual) | Interventional | 2010-06-30 | Terminated (stopped due to The ICTuS 2 portion of the trial has been halted and data will be analyzed.) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Mortality prior to the 90-day evaluation. (NCT01123161)
Timeframe: 90 days
Intervention | participants (Number) |
---|---|
Group1: IV t-PA and Normothermia | 5 |
Group 2 : IV t-PA and Hypothermia and Anti-shivering Treatment | 10 |
Incidence (number) of any intracranial hemorrhage (ICH) (whether or not symptomatic) within 48 hours of stroke onset will be presented by treatment group and overall. (NCT01123161)
Timeframe: 48 hours
Intervention | participants (Number) |
---|---|
Group1: IV t-PA and Normothermia | 13 |
Group 2 : IV t-PA and Hypothermia and Anti-shivering Treatment | 9 |
Incidence (number) of Symptomatic ICH (sICH) within 48 hours of stroke onset will be presented by treatment group and overall. Patients with neuroworsening (4 or more point increase in NIHSS , or a decline in the NIHSS consciousness item 1A score of more than 1 point, or a motor deterioration lasting more than 8 hours, all not due to iatrogenic cause) and hemorrhage seen on brain images in whom the investigator attributes the clinical change to the hemorrhage. (NCT01123161)
Timeframe: 48 hours
Intervention | participants (Number) |
---|---|
Group1: IV t-PA and Normothermia | 2 |
Group 2 : IV t-PA and Hypothermia and Anti-shivering Treatment | 1 |
Number subjects diagnosed with pneumonia according to CDC criteria will be presented by treatment group and overall, regardless of seriousness (NCT01123161)
Timeframe: 7 days or discharge whichever comes first
Intervention | participants (Number) |
---|---|
Group1: IV t-PA and Normothermia | 6 |
Group 2 : IV t-PA and Hypothermia and Anti-shivering Treatment | 12 |
The National Institutes of Health Stroke Scale (NIHSS) is used to quantify neurological deficit. The scale ranges from 0 (best) to 42 points (worst). Between scores of 0 to 42, higher values reflect progressively greater deficit. (NCT01123161)
Timeframe: 90 days
Intervention | units on a scale (Mean) |
---|---|
Group1: IV t-PA and Normothermia | 6.1 |
Group 2 : IV t-PA and Hypothermia and Anti-shivering Treatment | 4.8 |
The Barthel index measures independence in activities of daily living from 0 (worst) to 100 (best) in 5 point increments. Higher scores between 0 and 100 reflect progressively greater levels of independence. Scores were dichotomized at 90 so that a score of 95 or 100 was considered a successful treatment. (NCT01123161)
Timeframe: 90 days
Intervention | participants (Number) |
---|---|
Group1: IV t-PA and Normothermia | 25 |
Group 2 : IV t-PA and Hypothermia and Anti-shivering Treatment | 24 |
Modified Rankin describes disability: 0 is free of any disability or symptoms, 6 is death, and higher grades between 0 and 6 reflect progressively greater disability (NCT01123161)
Timeframe: 90 days
Intervention | participants (Number) |
---|---|
Group1: IV t-PA and Normothermia | 21 |
Group 2 : IV t-PA and Hypothermia | 21 |
2 reviews available for buspirone and Stroke
Article | Year |
---|---|
Interventions for treating anxiety after stroke.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Buspirone; Depression; Humans; Middle Aged; Par | 2017 |
Interventions for treating anxiety after stroke.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Buspirone; Humans; Paroxetine; Psychotherapy; R | 2011 |
2 trials available for buspirone and Stroke
Article | Year |
---|---|
EuroHYP-1: European multicenter, randomized, phase III clinical trial of therapeutic hypothermia plus best medical treatment vs. best medical treatment alone for acute ischemic stroke.
Topics: Analgesics, Opioid; Anti-Anxiety Agents; Brain Ischemia; Buspirone; Clinical Protocols; Europe; Huma | 2014 |
Determinants of effective cooling during endovascular hypothermia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Area Under Curve; Bu | 2012 |
4 other studies available for buspirone and Stroke
Article | Year |
---|---|
Beneficial effects of buspirone in endothelin-1 induced stroke cachexia in rats.
Topics: Animals; Buspirone; Cachexia; Cytokines; Endothelin-1; Glucose; Interleukin-6; Lipids; Muscle, Skele | 2023 |
Combining robotics with enhanced serotonin-driven cortical plasticity improves post-stroke motor recovery.
Topics: Animals; Buspirone; Mice; Neuronal Plasticity; Recovery of Function; Serotonin; Stroke; Stroke Rehab | 2021 |
Ice-cold saline for the induction of mild hypothermia in patients with acute ischemic stroke: a pilot study.
Topics: Acute Disease; Aged; Analgesics, Opioid; Blood Cell Count; Blood Chemical Analysis; Brain Ischemia; | 2009 |
The prolactin response to buspirone in poststroke depression: a preliminary report.
Topics: Adult; Aged; Buspirone; Case-Control Studies; Depression; Dominance, Cerebral; Female; Humans; Male; | 2000 |